Deprenorm mV Table n / a film about prolong. 35mg 60 pc

Description

Composition
Active substance:
1 tablet contains: 35.0 mg of trimetazidine dihydrochloride.
Excipients:
Calcium hydrogen phosphate dihydrate 34.6 mg; giproloza (hydroxypropylcellulose), 6.0 mg; hypromellose (hydroxypropylmethylcellulose) 64.0 mg; copovidone 4.2 mg; colloidal silicon dioxide (Aerosil) 6.4 mg; Magnesium stearate 0.8 mg; 59.0 mg microcrystalline cellulose; shell composition: Selekoat AQ-01673 7.0 mg [hypromellose (hydroxypropylmethylcellulose) 2.8 mg; macrogol – 400 (polyethylene glycol – 400) 0.7 mg; macrogol – 6000 (polyethylene glycol – 6000) 0.7 mg; Aluminum lacquer dye crimson [Ponceau 4 R] (E 124) 0.7 mg; Titanium dioxide 2.1 mg].
Description:
Tablets, film-coated pink, round, biconvex. The slight roughness. The cross-sectional view – almost white color.
Product form:
Prolonged action tablets, film-coated, 35 mg.
At 10 or 30 tablets in blisters of PVC film and aluminum foil printed patent.
1, 2, 3, 6 contour cell packs of 10 pills, or 1, 2, 3, 4 contour cell packs of 30 tablets together with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to any component of the drug; severe renal impairment (creatinine clearance less than 15 mL / min); expressed human liver; pregnancy; breastfeeding; age 18 years (effectiveness and safety have been established).
Dosage
35 mg
Indications
Ischemic heart disease: prevention of attacks of stable angina (as part of combination therapy); chorioretinal disorders with an ischemic component; vestibular-cochlear disorders ischemic nature, such as dizziness, tinnitus, hearing loss.
Interaction with other drugs
No information.
Overdose
Data on cases of overdose is limited. In the case of an overdose should be symptomatic therapy.
pharmachologic effect
Pharmacological group:
Antihypoxanth means.
Pharmacodynamics:
Trimetazidine has antihypoxia action in stable angina. Directly affecting the cardiomyocytes and neurons in the brain, it improves their metabolism and function. Cytoprotective effect is due to an increase in potential energy, the activation of the oxidative decarboxylation and the rationalization of consumption of oxygen (aerobic glycolysis increased and fatty acid oxidation blockade). Supports myocardial contractility, prevents a decrease in intracellular adenosine triphosphate (ATP) and creatine phosphate. In acidosis conditions normalize the functioning of membrane ion channels and prevents the accumulation of calcium and sodium in cardiomyocytes normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate content caused by myocardial ischemia and reperfusion. Prevents the damaging action of free radicals, preserves the integrity of cellular membranes, prevents activation of neutrophils in the ischemic area, increases the electric potential decreases the yield of creatine from the cells and the severity of ischemic myocardial injury.
Trimetazidine reduces the frequency of angina attacks (reduced intake of nitrate) through 2 weeks of increased exercise capacity, reduced blood pressure sharp fluctuations. Reduces dizziness and tinnitus.
When vascular eye disease improves the functional activity of the retina eyes.
Pharmacokinetics:
After taking the drug inside Trimetazidine is rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability – 90%. The time to reach maximum plasma concentration -. 5 h equilibrium state is reached after 60 hours, volume of distribution of 4.8 l / kg, suggesting good diffusion distribution in tissues.. Communication with plasma proteins – 16%. Easily penetrates the blood-tissue barriers. The half-life (T1 / 2) is about 7 hours, in patients older than 65 years -. About 12 hours is derived from the body by the kidneys (approximately 60% unchanged).
Renal clearance of trimetazidine is directly correlated with creatinine clearance (CC), hepatic clearance decreases with age.
Pregnancy and breast-feeding
The drug is contraindicated in pregnancy because of the lack of clinical data on the safety of its use.
It is unknown whether trimetazidine is excreted in breast milk. Therefore, when the need to apply during lactation discontinue breastfeeding.
Conditions of supply of pharmacies
On prescription.
side effects
The frequency of adverse effects reported when receiving trimetazidine, refer to the following gradation: very often (1/10); frequently (more than 1/100, less than 1/10); infrequently (more than 1/1000, 1/100 less); slowly (over 1/10000, 1/1000 less); very rare (less than 1/10000), including isolated reports.
From the digestive system
Common: abdominal pain, diarrhea, dyspepsia, nausea, vomiting.
On the part of the central nervous system
Common: dizziness, headache, asthenia.
Very rare: extrapyramidal disorder (tremor, rigidity, akinesia), reversible after discontinuation of the drug.
For the skin
Common: skin rash, pruritus, urticaria.
Cardio-vascular system
Rare: Orthostatic hypotension, “tides” of blood to the skin.
special instructions
Deprenorm® MB is not intended for the relief of angina attacks, for the initial course of therapy of stable angina or myocardial infarction.
In the case of angina attack should review and adapt the treatment.
The effect on the ability to transport and carry out work requiring high speed psychomotor reactions:
Use of the drug has no effect on the ability to drive the vehicle and the performance of work requiring high rate of psychomotor reactions.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Inside, during a meal time.
Deprenorm® MB take 1 tablet 2 times a day (morning and evening). The course of treatment – on the advice of a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist